4-DifluoroMethoxy-3-hydroxybenzaldehyde

Hefei Tianrui Pharmaceutical Chemical Co., Ltd. is located in the Industrial Park of Huagang Town, Feixi County, Hefei City. With excellent R&D capabilities, a complete set of complementary industrialization support, and an international CGMP quality management system, Tianrui is committed to providing professional technical services and commercialization of small molecule specialty APIs, CGMP standard intermediates, functional pharmaceutical excipients, and MRNA vaccine vectors for domestic and overseas well-known pharmaceutical enterprises. The company has independently developed and commercialized a range of new drug products, including Roflumilast, Rivaroxaban, Ezetimibe, Dasatinib, Repaglinide, Prucalopride Succinate, Salcaprozate sodium (8-(2-hydroxybenzamido)octanoate), Vandetanib, Garenoxacin, Ropinirole hydrochloride, Conivaptan hydrochloride, Crizotinib, Olaparib, Macitentan, Difamilast, Tepotinib, Tanimilast, Foscarbidopa, etc. Among them, Salcaprozate sodium (8-(2-hydroxybenzamido)octanoate) has successfully obtained registration numbers from both the Chinese CDE and the US FDA (CDE registration number: F20220000072; USDMF number: 037135). Meanwhile, we also have strength of long chain intermediates such as 8-Bromooctanoic Acid, 8-Aminooctanoic Acid, Methyl 8-bromooctanoate, Ethyl 8-bromooctanoate, 6-Bromohexanoic Acid, Ethyl 7-bromooctanoate, Diphenyl Phosphate, Tetrabenzyl pyrophosphate, 4-(Boc-Amino)cyclohexanone, etc. The products are mainly exported to Europe, North America, India, Japan, Korea and other countries, and we can provide the documentation support and audit requirements of the said corresponding regulatory markets. Tianrui Pharmaceutical is dedicated to the lifelong mission of striving for human health, continuously updating excellent products and services, and making contributions to breaking through the global barriers in the pharmaceutical industry.